Cargando…

Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study TILOT

BACKGROUND: Plaque psoriasis is a chronic inflammatory disorder affecting the skin and impacting quality of life. Tildrakizumab (TIL) is an IL‐23 inhibitor licensed for moderate‐to‐severe plaque psoriasis. Regulatory approval of medicinal products is based on safety and efficacy data from randomized...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsianakas, Athanasios, Schwichtenberg, Uwe, Pierchalla, Peter, Hinz, Torsten, Diemert, Sebastian, Korge, Bernhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles and Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087575/ https://www.ncbi.nlm.nih.gov/pubmed/36066998 http://dx.doi.org/10.1111/jdv.18572

Ejemplares similares

Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)
por: Narcisi, Alessandra, et al.
Publicado: (2022)

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
por: Burlando, Martina, et al.
Publicado: (2021)

Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
Publicado: (2021)

Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study
por: Caldarola, Giacomo, et al.
Publicado: (2022)

A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis
por: Becher, Gabrielle, et al.
Publicado: (2022)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Erythrodermic psoriasis improved by Tildrakizumab
por: Trevisan, Giampaolo, et al.
Publicado: (2022)

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
por: Beck, Kristen M, et al.
Publicado: (2018)

Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice
por: Ruggiero, A., et al.
Publicado: (2021)

Tildrakizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019)

Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis
por: Di Brizzi, Eugenia Veronica, et al.
Publicado: (2023)

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
por: Näslund-Koch, Charlotte, et al.
Publicado: (2020)

Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO
por: Reich, Kristian, et al.
Publicado: (2021)

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy
por: Pithadia, Deeti J., et al.
Publicado: (2019)

Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?
por: Megna, Matteo, et al.
Publicado: (2021)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
por: VAN MUIJEN, Marloes E., et al.
Publicado: (2022)

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis
por: Carrico, Justin, et al.
Publicado: (2020)

Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study
por: Menter, M.A., et al.
Publicado: (2020)

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
por: Ruggiero, Angelo, et al.
Publicado: (2023)

A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
por: Damsin, Thomas
Publicado: (2023)

Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients
por: Campione, Elena, et al.
Publicado: (2023)

Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor
por: Gooderham, M., et al.
Publicado: (2019)

Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis
por: Galluzzo, Marco, et al.
Publicado: (2022)

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies
por: Kimball, A.B., et al.
Publicado: (2019)

Erythroderme Psoriasis nach COVID-19-Erkrankung
por: Demiri, Jeta, et al.
Publicado: (2022)

Erythroderme Psoriasis nach COVID-19-Erkrankung
por: Demiri, Jeta, et al.
Publicado: (2021)

Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1
por: Cantrell, W., et al.
Publicado: (2021)

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)
por: Igarashi, Atsuyuki, et al.
Publicado: (2021)

Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience
por: De, Abhishek, et al.
Publicado: (2020)

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab
por: Ghazawi, Feras M., et al.
Publicado: (2021)

Tildrakizumab ineffective in generalized granuloma annulare
por: Song, Eingun James
Publicado: (2020)

Spotlight on Topical Long-Term Management of Plaque Psoriasis
por: Carrascosa, Jose Manuel, et al.
Publicado: (2020)

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2
por: Fernandez, A.P., et al.
Publicado: (2022)

A Real-World Study to Assess the Effectiveness of Itolizumab in Patients with Chronic Plaque Psoriasis
por: Parthasaradhi, Anchala, et al.
Publicado: (2017)

Therapeutic Inertia in the Management of Moderate-to-Severe Plaque Psoriasis in Adolescents
por: MELIN, Audrey, et al.
Publicado: (2021)

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis
por: MÄLKÖNEN, Tarja, et al.
Publicado: (2022)

Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)
por: Imafuku, Shinichi, et al.
Publicado: (2021)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: BORRONI, Riccardo G., et al.
Publicado: (2021)

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab
por: Kimball, A.B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h63555ksqss8rjnllprs7mp0rr